Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials: how physicians should present these clinical trials to patients—phase I trials typically have very low response rates (5% to 10%)—and explain their purpose without exaggerating the likely results.
Tuesday, August 16, 2011
Cancer; Controversies in Phase I Clinical Trials
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment